Ilkka Kantola
 Professor; Head of Medical Division, Turku university Hospital

Docent,  Faculty of Medicine (University of Turku) ilkkan@utu.fi : https://orcid.org/0000-0002-6228-522X CURRICULUM VITAE OF ILKKA KANTOLA041117.pdf

  

  

  

4 of 10

  

  

  

---

• Natural course of Fabry disease with the p Arg227Ter (pR227*) mutation in Finland: Fast study  (2019)  
  • Molecular Genetics and Genomic Medicine
   Pietilä-Effati P, Saarinen JT, Löyttyniemi E, Autio R, Saarenhovi M, Haanpää MK, Kantola I

  
  

• Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data  (2019)  
  • Clinical Pharmacology and Therapeutics
   Simon Körver, Ulla Feldt‐Rasmussen, Einar Svarstad, Ilkka Kantola, Mirjam Langeveld

  
  

• Renal involvement in Fabry disease  (2019)  
  • Nephrology Dialysis Transplantation
   Ilkka M Kantola

  
  

• The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts  (2019)  
  • Molecular Genetics and Metabolism Reports
   Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M

  
  

• European expert consensus statement on therapeutic goals in Fabry disease  (2018)  
  • Molecular Genetics and Metabolism
   Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymanska A, Tondel C, Viana-Baptista M, Weidemann F, Hilz MJ, Hilz MJ

  
  

• Fabryn tauti, harvinainen lysosomaalinen kertymäsairaus  (2018)  
  • Erikoislääkäri
   Kantola I

  
  

• Ortostaattisen hypotension tutkiminen ja hoito  (2018)  
  • Lääkärilehti
   Ilkka Kantola, Antti Jula, Teemu Niiranen

  
  

• Relation of blood pressure and organ damage: comparison between feasible, noninvasive central hemodynamic measures and conventional brachial measures  (2018)  
  • Journal of Hypertension
   Lindroos AS, Langen VL, Kantola I, Salomaa V, Juhanoja EP, Siven SS, Jousilahti P, Jula AM, Niiranen TJ

  
  

• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial  (2018)  
  • Lancet
   Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators

  
  

• Verenpainetaudin, sepelvaltimotaudin ja sydämen vajaatoiminnan lääkehoito  (2018)  Farmakologia ja toksikologia Kantola I., Mervaala E.